Infectious Diseases
Infectious disease research has broad application for prevention, diagnosis, and treatment across different type of infectious diseases impacting Kaiser members and the local community. IHR researchers focus on translational and epidemiologic research, clinical trials, and public health.
The IHR clinical trials team provides access to important therapies to treat uncommon infectious diseases, such as clofazimine for non-tuberculosis mycobacterial infections through the Expanded Access program, or tecovirimat (TPOXX) for MPox through the Centers for Disease Control and Prevention.
Further details about the portfolio of research addressing all aspects of infectious disease are listed below and IHR-clinical trials.
Infectious Disease Researchers
Kristi Bronkan, PharmD, BCPS Senior Manager of Clinical Trials 
Featured Projects
Investigator: Jason M. Glanz, PhD
The goal of the Norovirus and Acute Gastroenteritis Among Older Adults (NOVA) study is to better understand how often older adults experience stomach illness, also known as acute gastroenteritis (or AGE), and how that illness impacts a person’s quality of life.
Funder: P95
Study End Date: 06/30/27
The goal of the Norovirus and Acute Gastroenteritis Among Older Adults (NOVA) study is to better understand how often older adults experience stomach illness, also known as acute gastroenteritis (or AGE), and how that illness impacts a person’s quality of life.
Funder: P95
Study End Date: 06/30/27
Investigator: Rebecca S. Boxer, MD, MS
The NCCAPS study aims to describe cancer treatment modifications made in response to COVID-19 in adult patients and characterize patient factors (pre-existing comorbidities, cancer type and treatment, and demographic factors) associated with short- and long-term outcomes of COVID-19. Study visits are conducted in tandem with existing clinic visits, and we utilize a remote (phone) consent process while patients are completing home isolation periods after COVID-19 diagnosis.
Funder: National Cancer Institute
Study End Date: Currently Open
The NCCAPS study aims to describe cancer treatment modifications made in response to COVID-19 in adult patients and characterize patient factors (pre-existing comorbidities, cancer type and treatment, and demographic factors) associated with short- and long-term outcomes of COVID-19. Study visits are conducted in tandem with existing clinic visits, and we utilize a remote (phone) consent process while patients are completing home isolation periods after COVID-19 diagnosis.
Funder: National Cancer Institute
Study End Date: Currently Open
Investigators: Ingrid A. Binswanger, MD, MPH, MS and Jason Glanz, PhD
The objective of this study is to examine the association between SARS-CoV-2 serology results and late complications of COVID-19 infection. The study will focus on chronic post-acute sequelae COVID-19 (PASC): symptoms persisting, returning, or arising 12 weeks after COVID-19 infection. Understanding this relationship could help determine the role of SARS-CoV-2 serology in clinical practice and public health, such as whether routine screening is warranted. The study will include collecting self-reported data on PASC symptoms in several KP regions through a one-time survey to individuals who have received a SARS-CoV-2 antibody test. The resultant data will be linked to electronic health record (EHR) data on demographics, diagnoses, laboratory data, and utilization.
Funder: Garfield Memorial Fund
Study End Date: 02/28/2023
The objective of this study is to examine the association between SARS-CoV-2 serology results and late complications of COVID-19 infection. The study will focus on chronic post-acute sequelae COVID-19 (PASC): symptoms persisting, returning, or arising 12 weeks after COVID-19 infection. Understanding this relationship could help determine the role of SARS-CoV-2 serology in clinical practice and public health, such as whether routine screening is warranted. The study will include collecting self-reported data on PASC symptoms in several KP regions through a one-time survey to individuals who have received a SARS-CoV-2 antibody test. The resultant data will be linked to electronic health record (EHR) data on demographics, diagnoses, laboratory data, and utilization.
Funder: Garfield Memorial Fund
Study End Date: 02/28/2023